Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
<strong>Background</strong> Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate-to-severe chronic kidney disease are unknown....
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
American Heart Association
2018
|
| Subjects: |